Novo Nordisk's insulin aspart franchise is a DKK 10.6 billion ($1.5 billion) business worldwide, with NovoLog (known as NovoRapid outside ... and a 10ml multiple-dose vial should be administered ...

That suggests its top-selling insulin products like rapid-acting NovoRapid (insulin aspart), premix NovoMix (insulin aspart/insulin aspart protamine) and long-acting Tresiba (insulin degludec ...

Novo Nordisk has stated that its flagship insulin brand Mixtard will continue to be available in India in vial form, even as ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as it phases out its penfill. The penfill is being phased out as part ...